Dacomitinib(Vizimpro)

Dacomitinib blocks tumor cell signaling pathways through its unique mechanism of action, thereby inhibiting the proliferation and growth of tumor cells.

15mg*30tablets
45mg*30tablets

WhatsApp

To ensure medication safety, consult customer service for free before purchasing. Returns/exchanges are not accepted except for quality issues.

Authentic

Guarantee

Fast Delivery

Privacy

Dacomitinib Drug News

FDA Approves Vizimpro (dacomitinib) for the First-Line Treatment of Patients with EGFR-Mutated Metas

September 27, 2018 - Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration (FDA) has approved Vizimpro [vih-ZIM-pro] (daco···【Read More】
Update: 28 Feb,2026Source: Haiou HealthViews: 71

Frist Prev 1 1/1 Next Last

Bigbear Pharmaceutical

Dacomitinib(Vizimpro)

Dacomitinib Drug News

Recommended

FDA Approves Vizimpro (dacomitinib) for the First-Line Treatment of Patients with EGFR-Mutated Metas